Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Rhea-AI Summary
Aytu BioPharma will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. The company, led by CEO Josh Disbrow, plans to host a webcasted fireside chat at 1:15pm ET and engage in one-on-one investor meetings. The event will be held virtually, and interested parties can access the webcast via the conference home page or directly through a provided link. The webcast will also be available for replay. To schedule a one-on-one meeting, investors should contact Lytham Partners or register on the event's website.
Positive
- Aytu BioPharma is actively engaging with investors through the Lytham Partners Spring 2024 Investor Conference.
- CEO Josh Disbrow will participate in a webcasted fireside chat, providing transparency and direct communication with stakeholders.
- The virtual format allows for broader participation and accessibility for investors.
- The webcast will be available for replay, increasing exposure and information dissemination.
Negative
- The press release lacks specific financial or clinical updates, leaving investors without new concrete data on company performance.
- No mention of new product launches or significant business developments, which could be seen as a lack of progress.
News Market Reaction – AYTU
In the trading session that priced this news, AYTU gained 1.87%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
Webcast
The webcasted fireside chat will take place at 1:15pm ET on Thursday, May 30, 2024. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2024/ or directly at https://wsw.com/webcast/lytham11/aytu/2126355. The webcast will also be available for replay following the event.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/spring2024invreg/.
About Aytu BioPharma, Inc.
Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.
Contacts for Investors:
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com
Robert Blum or Roger Weiss
Lytham Partners
AYTU@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on accesswire.com